Catalent Pharma Solutions

From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 75 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing results.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.wpv-pagination-nav-links[data-toolset-views-view-pagination-block="33746bd812994fc2d16011719be6c6d7"] { text-align: left;justify-content: flex-start; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] { text-align: center; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link { background-color: rgba( 6, 147, 227, 1 );font-size: 16px;font-weight: bold; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link:hover { background-color: rgba( 142, 209, 252, 1 );border-radius: 5px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon { font-family: dashicons;margin-left: 8px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon::before { content: '\f465'; }   .tb-field[data-toolset-blocks-field="2352d76bb895ac4d7e6623b3996ba2ab"] { font-weight: bold; }  .tb-fields-and-text[data-toolset-blocks-fields-and-text="be25192e3b17b888e76f432f0e43e989"] { background-color: rgba( 142, 209, 252, 1 );padding-top: 5px;padding-bottom: 5px; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="03586fe69ea5b5174ebf265d564b8feb"] { padding: 0px 0px 5px 0px;margin-bottom: 10px;border-bottom: 2px solid rgba( 204, 203, 203, 1 ); } h3.tb-heading[data-toolset-blocks-heading="993a682c67afb3c5e9ef718484910c20"]  { font-size: 16px;color: rgba( 0, 51, 153, 1 );padding-bottom: 5px; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Company Details

Catalent Pharma Solutions

14 Schoolhouse Road, Somerset, NJ, 08873, United States

+1 866 720 3148

Website

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

Videos and Podcasts | July 13, 2016 | Lucid Group Communications Limited

The winning programme - Treating beyond symptoms in IBD: The Steroid Assessment Tool. Our approach to medical education is really helping to improve patient outcomes and change lives.

Unlimited wins at Communiqué Awards

Press Releases | July 11, 2016 | Health Unlimited

Health Unlimited, Liberation Unlimited and Rock Unlimited all win the judges’ approval.

Lucid Group shines at the Communiqué Awards

Press Releases | July 8, 2016 | Lucid Group Communications Limited

Lucid Group’s commitment to be a leader in medical education was recognised at the Communiqué Awards 2016 in London last night, where the agency received three awards, including being highly...

What have you learned about your customers recently?

White Papers and Resources | July 6, 2016 | Anthill Agency

Your customer-facing staff continually gets told about the needs and wants of your customers. Are you learning what they are learning?

Infographic: HIV Market Snapshot

White Papers and Resources | July 6, 2016 | Inizio

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

White Papers and Resources | July 6, 2016 | Inizio

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

White Papers and Resources | July 6, 2016 | Inizio

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

White Papers and Resources | July 6, 2016 | Inizio

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology...

Case Study: Oncology diagnostic biomarker landscaping study

White Papers and Resources | July 6, 2016 | Inizio

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...

Research Partnership publishes 2016 Living with RA reports

White Papers and Resources | July 6, 2016 | Inizio

Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.